|
|
 |
|
Viewing report
|
|
|
|
ExecSense Online Conference: Exit Strategy Options for Biotech/Pharmaceutical Companies in 2011-2012
ExecSense, May 2011, Pages: 60
In Exit Strategy Options for Biotech & Pharmaceutical Companies in 2011-2012, ExecSense examines what CEOs, CFOs (and their management teams) need to know about why the next year is a good time to consider selling their company to a strategic partner, competitor, or private equity fund. Take the time to view this online conference from the comfort of your office (on your computer, mobile phone, iPad, or printed out) to make sure you fully understand who is making acquisitions, current deal terms, how to increase your valuation and why many industry experts are saying the next 24 months could be one of the best times in the near future to consider selling your biotech/pharmaceutical company.
Upon ordering, ExecSense will email you a link to download the webinar files for viewing on your computer, mobile phone, iPod, iPad, Kindle or printed out. The downloaded files will include the PowerPoint presentation, audio narration and jpeg images of the slides (for watching on your mobile media device). Take advantage of your next commute, flight, business trip, lunch, or free hour in your schedule to view this webinar.
This online conference features the insights of a panel of investment bankers, industry analysts and lawyers that all have extensive experience specifically working with biotech/pharmaceutical companies, and focuses on:
- Everything you need to know about the best exit strategy options for biotech and pharmaceutical companies in 2011-2012
- Perspectives from leading biotech/pharmaceutical investment bankers on why the next 24 months may be a very good time to consider selling your company
- A list of the biotech/pharmaceutical companies that are most actively doing acquisitions right now, what types of companies they are buying, important deal points to note about their most recent acquisitions, and how to best position your company to create a bidding type atmosphere to get you the highest valuation possible
- Alternative options to selling your entire company, including selling a minority or majority stake in the company due to favorable tax laws for 2012, estate planning opportunities, and the current state and volatility of the financial markets
- A comprehensive overview of being acquired versus a merger, reverse-merger, IPO, and other potential exit strategies, including a detailed look at the financial and legal sides of each strategy and how they would impact management, employees, and investors/shareholders
- How to identify and approach a strategic partner, competitor, or private equity fund that is the optimal fit for acquiring your company
- The 10 questions most frequently asked by CEOs and CFOs of biotech/pharmaceutical companies about what factors impact their company's valuation and attractiveness to buyers (or public investors), and what they should be doing right now to best position their company for a successful exit strategy
- Case studies of other biotech and pharmaceutical companies that have recently sold in the current economic environment, what had the greatest impact on getting them the best deal terms and valuation possible, and key lessons for positioning your own company for a successful exit strategy
- This online conference also includes a 15-page research report featuring comparable analysis of acquisitions in the biotech/pharmaceutical industry, the most up-to-date information on biotech/pharmaceutical company valuations, acquisition deal terms, negotiation strategies, tax strategies, and more, including a detailed look at the financial and legal sides of key deal terms and how they would impact the CEO, management, employees, and investors/shareholders
Praise for ExecSense:
'Dynamic, up-to-date resource...' - Tina Ferguson, CEO of Rapid Success Partners
'Well organized, well articulated, and easy to follow...the best virtual learning experience I've had in quite some time.' - Brian K. Moore, HR Communications, Humana
'...convenient and on-point...an intelligent discussion on a very relevant subject.' - Meghan Wulff, Focus Management Group
|
|
|
|
